Physician profile
John D Holcomb
NPI 1124025267
$23,106.46
in general payments reported to CMS, 2019-2025
9 companies · $2,431 in 2025
The $2,431 reported for 2025 was more than what 94% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,482 · 2020: $6,493 · 2021: $670 · 2022: $434 · 2023: $4,959 · 2024: $2,638 · 2025: $2,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,907 · Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,907.11 |
| Food and Beverage | $1,121.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,926.71 | 2022-2025 | |
| Allergan, INC. | $6,493.72 | 2019-2022 | |
| Apyx Medical Corporation | $5,209.45 | 2019-2020 | |
| Merz North America, INC. | $1,039.90 | 2019-2025 | |
| Galderma Laboratories, L.P. | $310.82 | 2019-2025 | |
| Integra Lifesciences Corporation | $72.51 | 2023-2025 | Integra, Omnigraft, Surgimend |
| Lumenis, INC | $19.71 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $18.48 | 2019 | |
| Organogenesis INC. | $15.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Holcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.